ERBB2 and lymphoma: Two ADCs, trastuzumab emtansine (T-DM1, Kadcyla) and brentuximab vedotin (Adcetris), have been approved for the treatment of human epidermal growth factor receptor-2 (HER2)-positive metastatic and recurrent breast cancer and lymphoma, respectively [3].